Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 13889
Sealed predictions
- RAB11FIP3 in dopamine neurons, braak+0.24 (p 0.529) → -0.67 (p 0.047)receipt 13896
Swarm cases
receipt 13896: RAB11FIP3 in dopamine neurons, braak
- power
- full sample -0.29 (p 0.235, n 18), 95% CI -0.67 to +0.20. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.31 (p 0.204, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.24 (p 0.328, n 18). could be the mix.
- skeptic
- leave-one-out range -0.42 to -0.20, sign flips 0; without severely affected donors -0.29 (p 0.235, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.65 (p 0.0034, n 18) vs -0.29 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RAB11FIP3 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up RAB11FIP3 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.82 p 0.0034 (needs p < 1.7e-4)
Receipts
loading the receipts